There’s more than one reason why experts are excited by the potential of CSL. The post Here's one reason why experts think the CSL share price can rise 65%! appeared first on The Motley Fool Australia ...

The biotech's shares have had a tough run, but the long-term story may not be broken. The post Could the CSL share price ...

This ASX healthcare giant is out of favour, but that may be where opportunity starts. The post Is it time to get greedy with CSL shares? appeared first on The Motley Fool Australia.

When two quality shares diverge, I think it is worth taking a closer look. The post Better buy? CSL vs Rio Tinto shares appeared first on The Motley Fool Australia.

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL and Mayne Pharma say they do not expect to be affected by Donald Trump's latest attempt to impose a ... Read More The ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Markets fared ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CSL has started construction ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...

CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.” The Australia-based biopharma and manufacturer is ...